RT Journal Article
SR Electronic
T1 Children with familial hypercholesterolemia display changes in LDL and HDL function: a cross-sectional study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.11.20214247
DO 10.1101/2020.11.11.20214247
A1 Christensen, Jacob J.
A1 Narverud, Ingunn
A1 Ruuth, Maija
A1 Heier, Martin
A1 Jauhiainen, Matti
A1 Ulven, Stine M.
A1 Bogsrud, Martin P.
A1 Kovanen, Petri T.
A1 Halvorsen, Bente
A1 Oda, Michael N.
A1 Wium, Cecilie
A1 Retterstøl, Kjetil
A1 Öörni, Katariina
A1 Holven, Kirsten B.
YR 2020
UL http://medrxiv.org/content/early/2020/11/13/2020.11.11.20214247.abstract
AB Background The functional status of lipoprotein particles contributes to atherogenesis. The tendency of plasma LDL particles to aggregate and the ability of HDL particles to induce and mediate reverse cholesterol transport associate with high and low risk for cardiovascular disease in adult patients, respectively. However, it is unknown whether children with familial hypercholesterolemia (FH) display lipoprotein function alterations.Hypothesis We hypothesized that FH children had disrupted lipoprotein function.Methods We analyzed LDL aggregation susceptibility and HDL-apoA-I exchange to apoA-I ratio (HAE/apoA-I ratio), and activity of four proteins that regulate lipoprotein metabolism (CETP, LCAT, PLTP and PON1) in plasma samples derived from children with FH (n = 47) and from healthy children (n = 56). Potential biological mechanisms behind any variation in lipoprotein functionalities were explored using an NMR-based metabolomics profiling approach.Results LDL aggregation was higher and HAE/apoA-I ratio was lower in FH children than in healthy children. LDL aggregation associated positively with LDL-C and negatively with triglycerides, and HAE/apoA-I ratio associated negatively with LDL-C. Generally, the metabolomic profile for LDL aggregation was a mirror image of that for HAE/apoA-I ratio.Conclusions FH children displayed increased atherogenicity of LDL and disrupted HDL function. These newly observed functional alterations in LDL and HDL may increase the risk for atherosclerotic cardiovascular disease in FH children.Competing Interest StatementDr. Christensen has received research grants and/or personal fees from Mills DA, unrelated to the content of this manuscript. Drs. Ruuth, Kovanen and Oorni have applied for a patent on the LDL aggregation method; otherwise they have no other relevant financial relationships to disclose. Dr. Ulven has received research grants from Tine DA, Mills DA, and Olympic Seafood, none of which are related to the content of this manuscript. Dr. Retterstol reports personal fees from Amgen, Mills DA, The Norwegian Medical Association, The Norwegian Directorate of Health, Sanofi, Takeda, Chiesi, Bayer, MSD, and research grants from Oslo Economics and Mills outside the submitted work. Dr. Heier has received a research grant from the Norwegian Diabetes Association for analyses included in this manuscript. Dr. Holven has received research grants and/or personal fees from Tine DA, Mills DA, Olympic Seafood, Amgen, Sanofi, and Pronova, none of which are related to the content of this manuscript. The other authors have no relevant financial relationships to disclose.Funding StatementThis work was funded by the University of Oslo (Oslo, Norway), the National Advisory Unit on FH at OUH (Oslo, Norway), the Throne-Holst Foundation for Nutrition Research (Oslo, Norway), the South-Eastern Regional Health Authority (Oslo, Norway), the Academy of Finland (#315568 and #332564 to KO), the Jane and Aatos Erkko Foundation (to MJ), the Finnish Foundation for Cardiovascular Research (to MJ and KO), the Aarne Koskelo Foundation (to KO), and the Novo Nordisk Foundation (to KO). Wihuri Research Institute is maintained by the Jenny and Antti Wihuri Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Regional Committee for Research Ethics in South East Norway approved the study, and the study protocol was in accordance with the declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSummary statistics are available in Supplementary Material, but individual level raw data will not be made available.apoA-Iapolipoprotein A-IapoBapolipoprotein BASCVDatherosclerotic cardiovascular diseaseBMIbody mass indexBCAAsbranched-chain amino acidsCETPcholesteryl ester transfer proteinDHAdocosahexaenoic acid;FAfatty acidsFHfamilial hypercholesterolemiaHAEHDL-apoA-I exchangeHDLhigh-density lipoproteinLAlinoleic acidLCATlecithin–cholesterol acyltransferaseLDLlow-density lipoproteinLDL aggr (PP)LDL aggregation (per particle)LDL aggr (TL)LDL aggregation (total load)LDLRLDL receptorMUFAmonounsaturated fatty acidsn3omega-3 fatty acidsn6omega-6 fatty acidsPCphosphatidylcholinePLTPphospholipid transfer proteinPON1paraoxonase-1PUFApolyunsaturated fatty acidsRCTreverse cholesterol transportSFAsaturated fatty acidsSMsphingomyelinsVLDLvery low-density lipoprotein